Recon: Trump says Pfizer will cut US prices; Sanofi targeted in EU vaccine antitrust investigation

• Trump to roll out plan aimed at lowering prescription drug prices (STAT)
• Trump announces Pfizer price cuts as White House presses drugmakers (Reuters)
• Dems go hard on ACA tax credits in shutdown negotiations (STAT)
• LifeMD to offer Novo's Ozempic at $499/month to eligible US cash-paying customers (Reuters)
• Top FDA drug regulator’s unusual criticism of a therapy gets Wall Street wagging (STAT)

• Sanofi says under investigation by European Commission over vaccines (Reuters)
• Commission carries out unannounced antitrust inspections in the vaccines sector (European Commission)
• AstraZeneca's US listing may pull other firms from London in its wake (Reuters)
• European Commission says it is carrying out raids at premises of company active in vaccines sector (Reuters)
• UK will not impose sales tax on private healthcare, minister says (Reuters)
• Under new CEO, Novo ends heart failure partnership with Japanese biotech (Endpoints)
• Rapid Flurry Of Late September EU Regulatory Developments (MedTech Insight)
• Indian Medtech Firms See Limited Impact From H-1B Visa Fee Hike, But R&D Collaboration Faces Risks (MedTech Insight)

• Indivior to stop marketing Opvee, controversial overdose-reversal medication (STAT)
• As investor for AHA, ‘Venture Valkyrie’ argues ‘good medicine is good business’ (STAT)
• Lilly’s head scientist discusses its GLP-1 pill, Alzheimer’s strategy, and finding promising ideas and startups (STAT)
• Push to create functional human eggs in the lab stumbles, pioneering fertility researcher reports (STAT)
• Crystalys Therapeutics launches with $205 million funding round for trials of gout drug (Reuters)
• Star gets $125M Series D as it begins Phase 3 in bleeding disorders (Endpoints)
• Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer (Endpoints)
• Merck makes the case for PAH drug Winrevair in patients with earlier disease (Endpoints)
• Barinthus’ reverse merger with private biotech; Sutro to lay off 33% of employees (Endpoints)
• AnaptysBio plans to split its pipeline from its royalty assets into two publicly traded companies (Endpoints)

• FDA expands early alert program to cover all medical devices (MedTech Dive)
• Medtech firms splitting into ‘haves’ and ‘have-nots’: EY (MedTech Dive)
• EssilorLuxottica wins FDA OK for myopia-slowing eyeglass lenses (MedTech Dive)
• Countdown To Shutdown: Some CDRH Operations Would Continue In Funding Freeze (MedTech Insight)
• Medical Device Weaponization: Section 232 Investigation (FDA Law Blog)

• Right direction or wrong track: Is RFK Jr.’s food policy really making America healthier? (Food Dive)
• How Kellanova uses AI to predict creative performance and drive KPIs (Food Dive)

• A former CDC director’s guide to seeing and stopping threats to America’s health (STAT)
• Walmart takes on wellness (Endpoints)
• After months of investigation on drug tariffs, Trump seals new levies with a social media post (Endpoints)